Nanomedicine approach to breast cancer treatment in clinical trial studies: A scoping review

سال انتشار: 1401
محل انتشار: هشتمین کنفرانس بین المللی یافته های نو در مامایی، زنان ،زایمان و نازایی
کد COI اختصاصی: ICMWMI08_034
زبان مقاله: انگلیسی
تعداد مشاهده: 322

نویسندگان

Student Research Committee, Shahrekord University of Medical Sciences, Shahrekord, Iran

چکیده

Introduction: Cancer has been one of the deadliest causes of death and its prevalence continues to grow. Breast cancer is a complex and inherently heterogeneous disease with morphology, molecular profiles and clinical behaviors with different treatments. In order to protect healthy tissues and organs from the side effects of drugs, the use of targeted drug delivery systems with multiple potentials that have created a revolution in the diagnosis and treatment of diseases is one of the solutions under research.Materials and Methods: The current study is a scoping review that aims to investigate the nanomedicine approach in breast cancer treatment in clinical trial studies. In the search of keywords nanoparticles, breast cancer, clinical trial along with their Mesh terms, were done without time limit. The quality of the studies was checked by the CONSORT checklist. Consort's ۲۵-item checklist consists of ۶ general sections as described ۱-title and abstract, ۲- introduction, ۳- methods, ۴- results, ۵- discussion and ۶- other information.Results: After searching in Search in Scopus, Web of science, Pubmed and Google Scholar search engine, ۱۷۸ articles were found. Of the ۱۷۸ articles found, ۵۰ articles were removed due to duplication and ۱۱۶ articles due to lack of relevance, and ۵ articles were removed from the remaining ۱۲ articles due to lack of access, and finally ۷ articles were included in the scoping analysis.Conclusion: Using the none approach reduces the side effects of chemotherapy drugs that are used in breast cancer. Nanoparticles -based formulations lead to specific targeting of breast cancer cells and high therapeutic use. The use of nanoparticles -based formulations also causes controlled, and prolonged

کلیدواژه ها

drug delivery, nanoparticles, breast cancer, clinical trial

مقالات مرتبط جدید

اطلاعات بیشتر در مورد COI

COI مخفف عبارت CIVILICA Object Identifier به معنی شناسه سیویلیکا برای اسناد است. COI کدی است که مطابق محل انتشار، به مقالات کنفرانسها و ژورنالهای داخل کشور به هنگام نمایه سازی بر روی پایگاه استنادی سیویلیکا اختصاص می یابد.

کد COI به مفهوم کد ملی اسناد نمایه شده در سیویلیکا است و کدی یکتا و ثابت است و به همین دلیل همواره قابلیت استناد و پیگیری دارد.